{"id":"ab1010","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AB1010 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways. This inhibition can lead to the reduction of cancer cell growth and proliferation.","oneSentence":"AB1010 is a small molecule that targets the PI3K pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:09.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT07174492","phase":"PHASE3","title":"Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-01-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":412},{"nctId":"NCT03127267","phase":"PHASE3","title":"Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients","status":"RECRUITING","sponsor":"AB Science","startDate":"2021-02-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":495},{"nctId":"NCT05441488","phase":"PHASE3","title":"Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AB Science","startDate":"2022-06-28","conditions":"Progressive Multiple Sclerosis","enrollment":800},{"nctId":"NCT02588677","phase":"PHASE2, PHASE3","title":"Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"AB Science","startDate":"2013-04","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":394},{"nctId":"NCT03761225","phase":"PHASE3","title":"Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2014-09","conditions":"Metastatic Castrate Resistant Prostate Cancer","enrollment":714},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT05047783","phase":"PHASE2","title":"Masitinib in Patients With Symptomatic Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2021-11-23","conditions":"Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019","enrollment":78},{"nctId":"NCT04622865","phase":"PHASE2","title":"Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-06-01","conditions":"SARS-CoV 2, COVID-19, Coronavirus Disease 2019","enrollment":200},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT00812240","phase":"PHASE3","title":"Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)","status":"TERMINATED","sponsor":"AB Science","startDate":"2009-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":335},{"nctId":"NCT05200169","phase":"EARLY_PHASE1","title":"Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects","status":"COMPLETED","sponsor":"AB Science","startDate":"2017-07-31","conditions":"Healthy Volunteers","enrollment":4},{"nctId":"NCT01449162","phase":"PHASE3","title":"Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids","status":"COMPLETED","sponsor":"AB Science","startDate":"2011-01","conditions":"Asthma","enrollment":420},{"nctId":"NCT03766295","phase":"PHASE3","title":"Masitinib Plus Gemcitabine in Pancreatic Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2014-07","conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":377},{"nctId":"NCT01694277","phase":"PHASE3","title":"Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-04","conditions":"Gastrointestinal Stromal Tumors","enrollment":258},{"nctId":"NCT03771040","phase":"PHASE3","title":"Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels","status":"COMPLETED","sponsor":"AB Science","startDate":"2016-12","conditions":"Asthma","enrollment":347},{"nctId":"NCT02490488","phase":"PHASE2, PHASE3","title":"Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients","status":"COMPLETED","sponsor":"AB Science","startDate":"2014-04","conditions":"Ovarian Cancer","enrollment":248},{"nctId":"NCT03556956","phase":"PHASE2, PHASE3","title":"Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2015-07","conditions":"Colorectal Cancer Metastatic","enrollment":219},{"nctId":"NCT01280565","phase":"PHASE3","title":"Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit","status":"TERMINATED","sponsor":"AB Science","startDate":"2011-01","conditions":"Metastatic Melanoma","enrollment":134},{"nctId":"NCT01433497","phase":"PHASE3","title":"Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2011-08","conditions":"Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free","enrollment":656},{"nctId":"NCT00866138","phase":"PHASE2","title":"Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3","status":"COMPLETED","sponsor":"AB Science","startDate":"2005-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00814073","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-12","conditions":"Indolent Systemic Mastocytosis","enrollment":135},{"nctId":"NCT02605044","phase":"PHASE3","title":"Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"AB Science","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":123},{"nctId":"NCT01470131","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"AB Science","startDate":"2011-05","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT01410695","phase":"PHASE2, PHASE3","title":"Masitinib in Refractory Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"AB Science","startDate":"2011-07","conditions":"Rheumatoid Arthritis (RA)","enrollment":324},{"nctId":"NCT00789633","phase":"PHASE3","title":"Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-11-25","conditions":"Pancreatic Cancer","enrollment":353},{"nctId":"NCT02009423","phase":"PHASE3","title":"Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence","status":"TERMINATED","sponsor":"AB Science","startDate":"2015-07","conditions":"Gastro-Intestinal Stromal Tumour","enrollment":7},{"nctId":"NCT00976118","phase":"PHASE2","title":"Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2006-02","conditions":"Alzheimer's Disease","enrollment":34},{"nctId":"NCT00913432","phase":"PHASE2","title":"Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AB Science","startDate":"2007-03","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT01450488","phase":"PHASE2","title":"Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2005-06","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT00998751","phase":"PHASE2","title":"Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)","status":"COMPLETED","sponsor":"AB Science","startDate":"2005-06","conditions":"Gastro-intestinal Stromal Tumours","enrollment":30},{"nctId":"NCT00842270","phase":"PHASE2","title":"Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma","status":"COMPLETED","sponsor":"AB Science","startDate":"2006-01","conditions":"Asthma","enrollment":44},{"nctId":"NCT00831974","phase":"PHASE2","title":"Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2004-10","conditions":"Mastocytosis","enrollment":23},{"nctId":"NCT01506336","phase":"PHASE2","title":"Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-10","conditions":"Gastro Intestinal Stromal Tumor","enrollment":44},{"nctId":"NCT00831922","phase":"PHASE2","title":"Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AB Science","startDate":"2004-09","conditions":"Rheumatoid Arthritis","enrollment":43},{"nctId":"NCT01266369","phase":"PHASE2","title":"Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation","status":"COMPLETED","sponsor":"AB Science","startDate":"2007-02","conditions":"Mastocytosis","enrollment":21},{"nctId":"NCT01045577","phase":"PHASE2","title":"A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AB Science","startDate":"2005-09","conditions":"Psoriasis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ALLERGIC GRANULOMATOUS ANGIITIS"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"CARDIAC FAILURE CHRONIC"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"EJECTION FRACTION DECREASED"},{"count":1,"reaction":"MYELOMA CAST NEPHROPATHY"},{"count":1,"reaction":"N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED"},{"count":1,"reaction":"PHLEBITIS"}],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["masitinib"],"phase":"phase_2","status":"active","brandName":"AB1010","genericName":"AB1010","companyName":"AB Science","companyId":"ab-science","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AB1010 is a small molecule that targets the PI3K pathway. Used for Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}